WO1989009058A1 - Pharmaceutical preparation containing a fluoride salt - Google Patents

Pharmaceutical preparation containing a fluoride salt Download PDF

Info

Publication number
WO1989009058A1
WO1989009058A1 PCT/EP1989/000326 EP8900326W WO8909058A1 WO 1989009058 A1 WO1989009058 A1 WO 1989009058A1 EP 8900326 W EP8900326 W EP 8900326W WO 8909058 A1 WO8909058 A1 WO 8909058A1
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical preparation
acid
methyl
fluoride salt
oestren
Prior art date
Application number
PCT/EP1989/000326
Other languages
French (fr)
Inventor
Lodewijk Pieter Cornalis Schot
Original Assignee
Akzo N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo N.V. filed Critical Akzo N.V.
Publication of WO1989009058A1 publication Critical patent/WO1989009058A1/en
Priority to DK224690A priority Critical patent/DK224690A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/42—Phosphorus; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the invention relates to a pharmaceutical preparation containing a fluoride salt.
  • Such preparations are known, in particular for treating osteoporosis.
  • Fluoride salts such as, for example, NaF and Na 2 PO 3 F stimulate the trabecular bone substance and are therefore suitable for treating osteoporosis.
  • a disadvantage of such preparations is that they cause cortical bone loss and a change in the structure of the cortical bone. As a consequence thereof, the bone becomes more brittle, which has in turn the consequence that more frequent and ready bone fractures, in particular hip fractures, occur.
  • bone-protecting steroids are used to prevent and/or treat osteoporosis and more generally, diseases which are the result of excessively low bone substance.
  • the invention therefore relates to a pharmaceutical preparation containing a fluoride salt and a steroid with the general formula:
  • R 1 H 2 , H(OR 5 ) or 0;
  • R 2 ( ⁇ R 6 ) ( ⁇ OR 7 ) ;
  • R 3 H or (1-4 C)alkyl in position 6 or 7;
  • R 4 (1-4 C)alkyl
  • R 5 H or (1-18 C)acyl
  • R 6 H or (1-4 C) hydrocarbon radical
  • R 7 H or (1-18 C)acyl; and the broken lines indicate the presence of an additional bond in the 4,5- or 5, 10-position.
  • (1-4 C)Alkyl is understood to mean methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl.
  • R 3 is preferably methyl and is, in addition, preferably situated in the ⁇ -position.
  • R 4 is preferably methyl.
  • (1-18 C) acyl is derived from an organic carboxylic acid containing 1-18 carbon atoms.
  • an organic carboxylic acid containing 1-18 carbon atoms As examples thereof mention may be made of: formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, trimethylacetic acid, valeric acid, caproic acid, capric acid, pelargonic acid, undecylenic acid, lauric acid, palmitic acid, oleic acid, phenylacetic acid, phenylpropionic acid, cyclopentylpropionic acid, cyclohexylcarboxylic acid, cyclooctylacetic acid, benzoic acid, fumaric acid, maleic acid, succinic acid, citric acid.
  • Hydrocarbon radical is understood to mean one of the groups designated above as (1-4 C)alkyl or an unsaturated variant thereof containing 2-4 carbon atoms, such as vinyl, ethynyl, allyl, propargyl, isopropenyl, butynyl or butadienyl.
  • R 6 is preferably ethynyl, R 7 then preferably being H.
  • Salts which are readily soluble in water such as NaF, KF and Na 2 PO 3 F are preferably used as fluoride salts. The greatest preference is for Na 2 PO 3 F.
  • steroids having the formula I which may be used according to the invention are: 17 ⁇ -ethyl-17 ⁇ -hydroxy- ⁇ 4 -oestrene, 17 ⁇ -hydroxy- ⁇ 4 -oestren-3-one,
  • the pharmaceutical preparations according to the invention can be prepared by known galenical techniques by converting the respective steroid compound and the fluoride salt into a form which is suitable for enteral (for example, oral or rectal, and preferably oral) use.
  • enteral for example, oral or rectal, and preferably oral
  • the steroid compound and the fluoride salt are mixed with or dissolved in a pharmaceutically acceptable carrier.
  • Such preparations are tablets, pills, dragees, pastilles, suppositories, powders, (micro) capsules, emulsions, suspensions and solutions.
  • the quantity of steroid in the preparation to be administered is 0.05-10.0 mg and usually 0.1-5.0 mg.
  • the quantity of fluoride salt in the preparations to be administered is 1-250 mg and usually 10-100 mg.
  • the daily dosage is usually 1-3 dosage units.
  • the pharmaceutically acceptable carriers may be composed of one or more of the following ingredients: starch (for example, potato starch, maize starch), sugars (for example, lactose), lubricants (magnesium stearate, stearic acid), binders (for example, amylopectin, polyvinylpyrrolidone), water, alcohol, glycerol and derivatives thereof, vegetable, animal and mineral oils and fats, fatty alcohols, silicones, lanolins, polyalkylene glycols, cellulose derivatives, silica, dispersants, emulsifiers, surface active substances, antioxidants, preservatives, etc.
  • starch for example, potato starch, maize starch
  • sugars for example, lactose
  • lubricants magnesium stearate, stearic acid
  • binders for example, amylopectin, polyvinylpyrrolidone
  • water for example, alcohol, glycerol and derivatives thereof, vegetable, animal and
  • the preparations according to the invention may suitably be used to prevent and/or treat diseases which occur as a consequence of an excessively low bone substance and in particular, of osteoporosis.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

The invention relates to a pharmaceutical preparation containing a fluoride salt and a steroid with the general formula (I), wherein R1 = H2, H(OR5) or O; R2 = (alphaR6) (betaOR7; R3 = H or (1-4 C)alkyl in position 6 or 7; R4 = (1-4 C)alkyl; R5 = H or (1-18 C)acyl; R6 = H or (1-4 C)hydrocarbon radical; R7 = H or (1-18 C)acyl; and the broken lines indicate the presence of an additional bond in the 4,5- or 5,10-position.

Description

Pharmaceutical preparation containing a fluoride salt.
The invention relates to a pharmaceutical preparation containing a fluoride salt.
Such preparations are known, in particular for treating osteoporosis. Fluoride salts such as, for example, NaF and Na2PO3F stimulate the trabecular bone substance and are therefore suitable for treating osteoporosis. A disadvantage of such preparations is that they cause cortical bone loss and a change in the structure of the cortical bone. As a consequence thereof, the bone becomes more brittle, which has in turn the consequence that more frequent and ready bone fractures, in particular hip fractures, occur.
It is further known that bone-protecting steroids are used to prevent and/or treat osteoporosis and more generally, diseases which are the result of excessively low bone substance.
Surprisingly, it has now been found that by using certain steroids in combination with said fluoride salts for preventing and/or treating such diseases and, in particular, osteoporosis, the disadvantages associated with the use of said fluoride salts can be reduced and/or be avoided. The invention therefore relates to a pharmaceutical preparation containing a fluoride salt and a steroid with the general formula:
Figure imgf000004_0001
wherein
R1 = H2, H(OR5) or 0;
R2 = (αR6) (βOR7) ;
R3 = H or (1-4 C)alkyl in position 6 or 7;
R4 = (1-4 C)alkyl;
R5 = H or (1-18 C)acyl;
R6 = H or (1-4 C) hydrocarbon radical;
R7 = H or (1-18 C)acyl; and the broken lines indicate the presence of an additional bond in the 4,5- or 5, 10-position.
(1-4 C)Alkyl is understood to mean methyl, ethyl, propyl, isopropyl, butyl, isobutyl or tert-butyl. R3 is preferably methyl and is, in addition, preferably situated in the α-position. R4 is preferably methyl.
As is already indicated by the affix (1-18 C), (1-18 C) acyl is derived from an organic carboxylic acid containing 1-18 carbon atoms. As examples thereof mention may be made of: formic acid, acetic acid, propionic acid, butyric acid, isobutyric acid, trimethylacetic acid, valeric acid, caproic acid, capric acid, pelargonic acid, undecylenic acid, lauric acid, palmitic acid, oleic acid, phenylacetic acid, phenylpropionic acid, cyclopentylpropionic acid, cyclohexylcarboxylic acid, cyclooctylacetic acid, benzoic acid, fumaric acid, maleic acid, succinic acid, citric acid. (1-4 C) Hydrocarbon radical is understood to mean one of the groups designated above as (1-4 C)alkyl or an unsaturated variant thereof containing 2-4 carbon atoms, such as vinyl, ethynyl, allyl, propargyl, isopropenyl, butynyl or butadienyl.
R6 is preferably ethynyl, R7 then preferably being H.
Salts which are readily soluble in water such as NaF, KF and Na2PO3F are preferably used as fluoride salts. The greatest preference is for Na2PO3F.
Examples of steroids having the formula I which may be used according to the invention are: 17α-ethyl-17β-hydroxy-Δ4-oestrene, 17β-hydroxy-Δ4-oestren-3-one,
7α-methyl-17α-ethynyl-17β-hydroxy-Δ5(10)-oestren-3-one, 7α-methyl-17α-ethynyl-Δ5(10)-oestren-17β-ol, 7α-methyl-17α-ethynyl-17β-hydroxy-Δ4-oestren-3-one, 7α-methyl-17α-ethyl-17β-hydroxy-Δ5(10)-oestren-3-one, 7α-methyl-17α-ethynyl-Δ5(10)-oestrene-3α,17β-diol, 7α-methyl-17α-ethynyl-Δ5(10)-oestrene-3β,17β-diol, 7α-methyl-17α-allyl-17β-hydroxy-Δ5(10)-oestren-3-one, 7α,17α-dimethyl-170-hydroxy-Δ4-oestren-3-one, 7o;-methyl-17α-ethynyl-Δ4-oestrene-3β,17β-diol, 6α-methyl-17β-hydroxy-Δ4-oestren-3-one, 6α-methyl-17β-hydroxy-Δ4-oestren-3-one, 6α-methyl-17α-ethynyl-17β-hydroxy-Δ4-oestren-3-one, 6α-methyl-17α-ethyl-17β-hydroxy-Δ4-oestren-3-one, 6α-methyl-17α-ethynyl-Δ4-oestren-17β-ol, 6α-methyl-17α-ethynyl-17β-hydroxy-Δ5(10)-oestren-3-one, 6α-methyl-17α-allyl-17β-hydroxy-Δ5(10)-oestren-3-one, and esters thereof. The greatest preference is for 7α-methyl-17α-ethynyl-17β-hydroxy-Δ5(10)-oestren-3-one. The pharmaceutical preparations according to the invention can be prepared by known galenical techniques by converting the respective steroid compound and the fluoride salt into a form which is suitable for enteral (for example, oral or rectal, and preferably oral) use. For this purpose, the steroid compound and the fluoride salt are mixed with or dissolved in a pharmaceutically acceptable carrier.
Examples of such preparations are tablets, pills, dragees, pastilles, suppositories, powders, (micro) capsules, emulsions, suspensions and solutions.
The quantity of steroid in the preparation to be administered is 0.05-10.0 mg and usually 0.1-5.0 mg. The quantity of fluoride salt in the preparations to be administered is 1-250 mg and usually 10-100 mg. The daily dosage is usually 1-3 dosage units.
The pharmaceutically acceptable carriers may be composed of one or more of the following ingredients: starch (for example, potato starch, maize starch), sugars (for example, lactose), lubricants (magnesium stearate, stearic acid), binders (for example, amylopectin, polyvinylpyrrolidone), water, alcohol, glycerol and derivatives thereof, vegetable, animal and mineral oils and fats, fatty alcohols, silicones, lanolins, polyalkylene glycols, cellulose derivatives, silica, dispersants, emulsifiers, surface active substances, antioxidants, preservatives, etc.
The preparations according to the invention may suitably be used to prevent and/or treat diseases which occur as a consequence of an excessively low bone substance and in particular, of osteoporosis.
The invention is explained on the basis of the following examples. Example 1 (tablet)
7α-Methyl-17α-ethynyl-17/3-hydroxy- Δ5(10)-oestren-3-one, 2.5 mg
Na2PO3F 50.0 mg
Potato starch 25.0 mg
Magnesium stearate 1.25 mg
Ascorbyl palmitate 0.5 mg
Amylopectin 5.0 mg
Lactose to 250.0 mg
Example 2 (tablet)
7α-Methyl-17α-ethyl-17β-hydroxy- Δ5(10)-oestren-3-one, 2.0 mg
Na2PO3F 30.0 mg
Maize starch 25.0 mg
Stearic acid 2.5 mg
Silica ("Aerosil") 2.5 mg
Polyvinylpyrrolidone 7.5 mg dl-α-Tocopherol 0.25 mg
Lactose to 250.0 mg
Example 3 (tablet)
7α-Methyl-17α-ethynyl-17β--ydroxy- Δ4-oestren-3-one, 5.0 mg
Na2PO3F 50.0 mg
Potato starch 62.5 mg
Magnesium stearate 10.0 mg dl-α-Tocopherol 0.5 mg
Lactose to 250.0 mg

Claims

Claims
1. Pharmaceutical preparation containing a fluoride salt and a steroid with the general formula:
Figure imgf000008_0001
wherein
R1 = H2, H(OR5) or 0;
R2 = (αR6) (βOR7);
R3 = H or (1-4 C)alkyl in position 6 or 7;
R4 = (1-4 C)alkyl;
R5 = H or (1-18 C)acyl;
R6 = H or (1-4 C)hydrocarbon radical;
R7 = H or (1-18 C)acyl; and the broken lines indicate the presence of an additional bond in the 4,5- or 5,10-position.
2. Pharmaceutical preparation according to Claim 1, characterized in that the fluoride salt is water- soluble.
3. Pharmaceutical preparation according to Claim 1-2, characterized in that the fluoride salt is a sodium salt.
4. Pharmaceutical preparation according to Claim 1-3, characterized in that the fluoride salt is Na2PO3F.
5. Pharmaceutical preparation according to Claim 1-4, characterized in that the steroid is 7α-methyl-17α- ethynyl-17β-hydroxy-Δ5(10)-oestren-3-one.
6. Pharmaceutical preparation according to Claim 1-5, characterized in that the quantity of steroid is 0.05-10.0 mg.
7. Pharmaceutical preparation according to Claim 1-6, characterized in that the quantity of salt is 1-250 mg,
PCT/EP1989/000326 1988-03-25 1989-03-24 Pharmaceutical preparation containing a fluoride salt WO1989009058A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DK224690A DK224690A (en) 1988-03-25 1990-09-18 PHARMACEUTICAL PREPARATION CONTAINING A FLUORIDE SALT

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL8800749 1988-03-25
NL8800749 1988-03-25

Publications (1)

Publication Number Publication Date
WO1989009058A1 true WO1989009058A1 (en) 1989-10-05

Family

ID=19852000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1989/000326 WO1989009058A1 (en) 1988-03-25 1989-03-24 Pharmaceutical preparation containing a fluoride salt

Country Status (5)

Country Link
EP (1) EP0406279A1 (en)
JP (1) JPH03503414A (en)
AU (1) AU3435989A (en)
DK (1) DK224690A (en)
WO (1) WO1989009058A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455503A1 (en) * 1990-05-04 1991-11-06 Colgate-Palmolive Company Composition for treating osteoporosis and hormonal imbalance
DE4236090C1 (en) * 1992-10-26 1994-01-05 Asta Medica Arzneimittel Pharmaceutical preparation for fluoride ion supply
WO2000023460A1 (en) * 1998-10-16 2000-04-27 Akzo Nobel N.V. HIGH PURITY COMPOSITION COMPRISING (7α,17α)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN- 5(10)-EN-20-YN-3-ONE

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287219A (en) * 1963-08-05 1966-11-22 Charles J Nemanick Method of healing bone fractures

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3287219A (en) * 1963-08-05 1966-11-22 Charles J Nemanick Method of healing bone fractures

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Rote Liste, 1980, Editio Cantor (Aulendorf, Wurtt., DE), no. 61051 B, "Calstabil" *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0455503A1 (en) * 1990-05-04 1991-11-06 Colgate-Palmolive Company Composition for treating osteoporosis and hormonal imbalance
GR910100192A (en) * 1990-05-04 1992-07-30 Colgate Palmolive Co Method for preparing a composition for the osteoporosis and hormone imbalance treatment
DE4236090C1 (en) * 1992-10-26 1994-01-05 Asta Medica Arzneimittel Pharmaceutical preparation for fluoride ion supply
WO2000023460A1 (en) * 1998-10-16 2000-04-27 Akzo Nobel N.V. HIGH PURITY COMPOSITION COMPRISING (7α,17α)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN- 5(10)-EN-20-YN-3-ONE
US6969708B1 (en) 1998-10-16 2005-11-29 Akzo Nobel N.V. Process for the preparation of a high purity composition comprising (7α, 17α)- 17-hydroxy- 7-methyl- 19-nor-17-pregn-5(10)-en-20-yn-3-one
CN100378116C (en) * 1998-10-16 2008-04-02 欧加农股份有限公司 High purity composition comprising (7a, 17a,)-17-hydroxy-7-methyl 19-nor-17-prege-5-(10)-en-20-yn-3-one

Also Published As

Publication number Publication date
DK224690D0 (en) 1990-09-18
DK224690A (en) 1990-09-18
JPH03503414A (en) 1991-08-01
EP0406279A1 (en) 1991-01-09
AU3435989A (en) 1989-10-16

Similar Documents

Publication Publication Date Title
EP0159739B1 (en) Steroids for use as immunomodulators
US5116828A (en) Pharmaceutical composition for treatment of osteoporosis
JP2965160B2 (en) Compositions that achieve contraception
KR101019361B1 (en) Pharmaceutical combination of ethinylestradiol and drospirenone for use as a contraceptive
US4071623A (en) Pharmaceutical preparation adapted for oral administration
EP1272505B1 (en) 8beta-substituted-11beta-pentyl- and 11beta-hexyl-estra-1,3,5(10)-triene derivatives
JPH0680072B2 (en) Estriol ester, process for producing the same and depot contraceptive containing the compound
US3859437A (en) Reducing cholesterol levels
AU756739B2 (en) Testosterone derivative
RU2482853C2 (en) Pharmaceutical composition, method for preparing it and multiphase pharmaceutical preparation for ovulation inhibition in mammal
AU8207691A (en) Method of treating human prostatic adenocarcinoma
US4117121A (en) Method of increasing bile flow and decreasing lipid levels
WO1989009058A1 (en) Pharmaceutical preparation containing a fluoride salt
AU671706B2 (en) Use of a Pregnane Derivative
JP2004524354A (en) Estrogen replacement therapy
SANANÈS et al. A role for prostaglandins in decidualization of the rat uterus
US4076811A (en) Novel agents and methods for treatment of climacteric disturbances
KR880701731A (en) 14,17β-Ethano-14β-Estratriene and Estratetene Process for preparing them and pharmaceutical composition containing them
JP2779931B2 (en) Psoriasis treatment
US4794119A (en) Aqueous crystalline suspension of steroid glycoesters
NZ236755A (en) Composition for alleviating menopausal symptoms comprising melatonin and an estrogen and/or an androgen.
JPH0759505B2 (en) Osteogenesis promoter containing cyclopentenones as active ingredients
GB1572488A (en) 1-hydroxy- 4-3-keto-estrenes and their use
CN1254341A (en) Pharmaceutically accpetable salts of 3-hydroxy-estr-5-(10)-en-17-one 3-sulphate active as estrogens
JPH0692308B2 (en) Antihyperlipidemic agent

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI JP KR US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1989903712

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1989903712

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1989903712

Country of ref document: EP